Assessment of oncofertility content on reproductive endocrinology and infertility clinic websites
ACADEMIC PRESS INC ELSEVIER SCIENCE. 2021: S93-S94
View details for Web of Science ID 000687070800165
IVF OUTCOMES IN A MULTI-CENTER ANALYSIS OF SINGLE OR COUPLED INTENDED FATHERS: BIOLOGY AND FATHERHOOD
ELSEVIER SCIENCE INC. 2021: E22
View details for Web of Science ID 000680508800030
INFLAMMATORY PROTEINS AS PREDICTORS OF DIMINISHED OVARIAN RESERVE
ELSEVIER SCIENCE INC. 2021: E4
View details for Web of Science ID 000680508800003
ASSESSMENT OF ONCOFERTILITY CONTENT ON REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY CLINIC WEBSITES
ELSEVIER SCIENCE INC. 2021: E35-E36
View details for Web of Science ID 000680508800051
The Influence of PrEP-Related Stigma and Social Support on PrEP-Use Disclosure among Women Who Inject Drugs and Social Network Members.
AIDS and behavior
Pre-exposure prophylaxis (PrEP) is a promising but underutilized HIV prevention strategy for Women who Inject Drugs (WWID). Stigma and disclosure concerns have been key barriers to PrEP use among women in PrEP efficacy trials. Social support has been found to buffer against some PrEP stigma, though these factors have been largely unexplored among WWID. Investigating how WWID disclose PrEP use is important given evidence that disclosure is associated with higher adherence. We aimed to identify the impact of stigma and support on PrEP disclosure within social networks of WWID participating in a PrEP demonstration project in Philadelphia, PA, USA. PrEP-using WWID≥18years completed social network surveys. Generalized estimating equations were used to account for the correlation of network structure. Thirty-nine WWID (i.e. egos) named an average of 9.5±3.3 network members (i.e. alters), for a total sample of 371 unique relationships. Egos disclosed their PrEP use to an average of 4.0 alters (SD=2.8). Related to PrEP stigma, participants had 0.4 times decreased odds of PrEP disclosure with alters who would disapprove of them taking PrEP (95% CI: 0.1-0.9). Related to support, participants had 2.5 times higher odds of disclosure among peers who could provide PrEP advice (95% CI: 1.0-6.0). Interventions that increase social support and decrease stigma are pivotal for increasing PrEP use disclosure among WWID.
View details for DOI 10.1007/s10461-021-03312-x
View details for PubMedID 34014430
EFFECT OF HORMONAL CONTRACEPTION ON ILLNESS SEVERITY IN WOMEN WITH POSITIVE SARS-COV2 TESTS.
ELSEVIER SCIENCE INC. 2020: E535–E536
View details for Web of Science ID 000579355301491
- Compassionate embryo transfer: part of a bigger question. Fertility and sterility 2020
Epigenetic clock measuring age acceleration via DNA methylation levels in blood is associated with decreased oocyte yield.
Journal of assisted reproduction and genetics
PURPOSE: To investigate how biologic age (phenotypic age at which your body functions) greater than chronologic age, (age acceleration (AgeAccel)), correlates with oocyte yield.METHODS: Thirty-nine women undergoing ovarian stimulation, inclusive of all infertility diagnoses, were included in this pilot study. Methylome analysis of peripheral blood was utilized to determine biologic age. AgeAccel was defined as biologic age >2years older than chronologic age. A negative binomial model was used to obtain the crude association of AgeAccel with number of oocytes. A parsimonious adjusted model for the number of oocytes was obtained using backwards selection (p<0.05).RESULTS: Measures of age were negatively correlated with number of oocytes (chronological age Pearson rho=-0.45, biologic age Pearson rho=-0.46) and AMH was positively correlated with number of oocytes (Pearson rho=0.91). Patients with AgeAccel were noted to have lower AMH values (1.29ng/mL vs. 2.29, respectively (p=0.049)) and lower oocyte yield (5.50 oocytes vs. 14.50 oocytes, respectively (p=0.0030)). A crude association of a 7-oocyte reduction in the age-accelerated group was found (-6.9 oocytes (CI -11.6, -2.4)). In a model with AMH and antral follicle count, AgeAccel was associated with a statistically significant 3.3 reduction in the number of oocytes (-3.1; 95% CI -6.5, -0.1; p=0.036).CONCLUSIONS: In this small pilot study, AgeAccel is associated with a lower AMH and lower oocyte yield providing preliminary evidence that biologic age, specifically AgeAccel, may serve as an epigenetic biomarker to improve the ability of predictive models to assess ovarian reserve.
View details for DOI 10.1007/s10815-020-01763-0
View details for PubMedID 32285295
- EPIGENETIC CLOCK MEASURING AGE ACCELERATION VIA DNA METHYLATION LEVELS IN BLOOD IS ASSOCIATED WITH DECREASED OOCYTE YIELD. ELSEVIER SCIENCE INC. 2019: E4–E5